Thursday, Illumina Inc (NASDAQ:ILMN) reported fourth-quarter 2023 sales of $1.12 billion, up 4% Y/Y, beating the consensus of $1.09 billion.
The company reported adjusted EPS of $0.14, surpassing the consensus estimate of $0.02.
The company shipped 79 NovaSeq X instruments in the fourth quarter of 2023 and 352 instruments for fiscal year 2023.
Illumina decided to divest GRAIL in December, with terms to be finalized by the end of the second quarter of 2024.
The company signed an agreement with Janssen Research & Development, a unit of Johnson & Johnson (NYSE:JNJ).
This ...